Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

UNITED THERAPEUTICS (UTHR) Cost of Revenue: 2009-2025

Historic Cost of Revenue for UNITED THERAPEUTICS (UTHR) over the last 17 years, with Sep 2025 value amounting to $100.9 million.

  • UNITED THERAPEUTICS's Cost of Revenue rose 21.42% to $100.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $356.9 million, marking a year-over-year increase of 17.09%. This contributed to the annual value of $309.7 million for FY2024, which is 20.27% up from last year.
  • As of Q3 2025, UNITED THERAPEUTICS's Cost of Revenue stood at $100.9 million, which was up 15.18% from $87.6 million recorded in Q2 2025.
  • Over the past 5 years, UNITED THERAPEUTICS's Cost of Revenue peaked at $100.9 million during Q3 2025, and registered a low of $23.0 million during Q1 2021.
  • Moreover, its 3-year median value for Cost of Revenue was $75.9 million (2024), whereas its average is $77.1 million.
  • In the last 5 years, UNITED THERAPEUTICS's Cost of Revenue declined by 20.16% in 2022 and then soared by 115.82% in 2023.
  • UNITED THERAPEUTICS's Cost of Revenue (Quarterly) stood at $34.6 million in 2021, then skyrocketed by 69.94% to $58.8 million in 2022, then increased by 20.75% to $71.0 million in 2023, then climbed by 6.90% to $75.9 million in 2024, then grew by 21.42% to $100.9 million in 2025.
  • Its last three reported values are $100.9 million in Q3 2025, $87.6 million for Q2 2025, and $92.5 million during Q1 2025.